Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/230496
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Prognostic value of VEGFR2 immunoexpression in glioblastoma |
Autor: | Issus, Gemma; Gibert, Joan; Navarro Medrano, Pilar CSIC ORCID; Arumi-Uria, Montserrat; Naranjo-Hans, Dolores; Bellosillo, Beatriz; Martínez-García, María; Alameda, Francesc | Palabras clave: | Glioblastoma VEGFR2 IDH1 MGMT Prognosis |
Fecha de publicación: | 2020 | Editor: | Sciedu Press | Citación: | Journal of Solid Tumors 10: 1-6 (2020) | Resumen: | Glioblastoma is the most frequent and aggressive primary tumor of the central nervous system. Prognosis is poor, with a median survival of 15 months after diagnosis. Various tumor biomarkers show prognostic value for glioblastomas, including VEGFR2, which is a receptor of VEGF related to the growth of the blood vessel network. VEGFR2 expression associates with poor prognosis in some tumors. Here we studied the prognostic value of the VEGFR2 immunohistochemical expression in glioblastoma. We used tissue microarrays to analyze 45 surgically excised samples from glioblastomas. Clinical data (age, sex, and Karnofsky Performance Status [KPS]) and morphological data (tumor necrosis, palisading, and vascular thrombosis) were collected. We performed a molecular study of MGMT and IDH1 expression (which are potential prognostic factors for glioblastomas) and an immunohistochemical study of VEGFR2 expression. Our results indicate that age, KPS, tumor necrosis, vascular thrombosis, treatment (STUPP versus other), and VEGFR2 immunoreactivity were related to prognosis (p < .005). In a multivariate analysis, only age > 65 years (Hazard Ratio (HR) (95% CI): 4.9 (2.1¿11.4), p < .01), and VEGFR2 immunoexpression (HR (95% CI): 2.8 (1.3¿6.1), p = .008), were found to have a statistically significant relation to prognosis. We conclude that immunohistochemical evaluation of VEGFR2 provides added prognostic value to the study of glioblastoma. | Versión del editor: | http://dx.doi.org/10.5430/jst.v10n1p1 | URI: | http://hdl.handle.net/10261/230496 | DOI: | 10.5430/jst.v10n1p1 | Identificadores: | doi: 10.5430/jst.v10n1p1 issn: 1925-4067 e-issn: 1925-4075 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
14839-57526-2-PB.pdf | 339,94 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
104
checked on 23-abr-2024
Download(s)
86
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.